Ming-Ming Zhou, PhD
img_Ming-Ming Zhou
PROFESSOR & CHAIR | Pharmacological Sciences
PROFESSOR | Oncological Sciences
CO-DIRECTOR, DRUG DISCOVERY INSTITUTE
Research Topics
Alzheimer's Disease, Biochemistry, Biophysics, Cancer, Chromatin, Drug Design and Discovery, Epigenetics, Gene Regulation, Inflammation, Structural Biology, T Cells, Transcription Factors
Multi-Disciplinary Training Area
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
Transcription Mechanism and Drug Discovery

The Zhou Lab investigates how genes are switched on and off within chromatin—the tightly packed structure that organizes our genome. Their research has led to major breakthroughs in understanding how DNA-packaging proteins, known as histones, regulate gene activity. In a landmark 1999 Nature study, Dr. Zhou and colleagues determined the first three-dimensional structure and function of the Bromodomain—a key module in gene-regulating proteins that recognizes chemical tags (specifically, acetyl groups) on histones. This discovery revealed how cells "read" histone modifications to control gene expression and directly inspired the influential "histone code" hypothesis proposed by C. David Allis in 2000.

The Zhou Lab’s work resolved a long-standing question in biology, first posed by Vincent Allfrey in 1964: How does histone acetylation influence gene activity? They demonstrated that acetylation not only loosens DNA-histone interactions, but also actively recruits regulatory proteins that modulate gene expression. This bromodomain-acetylation recognition mechanism is now known to play central roles in gene regulation, DNA repair, cell division, and other essential cellular processes.

Through structure-guided studies, The Zhou Lab has uncovered fundamental principles by which cells interpret histone "tags" to fine-tune gene expression. Key findings include:
• How bromodomain proteins organize chromatin structure and recruit gene-regulatory complexes to ensure faithful cell lineage differentiation (Mol. Cell, 2002, 2004, 2017);
• How combinations of histone modifications dictate gene activation or repression (Mol. Cell, 2007, 2010; Nature Struct. & Mol. Biol., 2008, 2020; Nature, 2010);
• How distinct chemical modifications on the same histone residue can produce divergent gene expression outcomes (Mol. Cell, 2023).

Dr. Zhou also pioneered the use of small molecules to modulate bromodomain-histone interactions—enabling chemical control of gene expression (JACS, 2005, 2011; JMC, 2012, 2013; Cancer Cell, 2014, 2015; PNAS, 2017, 2018). This work laid the foundation for a new class of bromodomain-targeted therapies currently under development for cancer, autoimmune diseases, and Alzheimer’s disease (Nature Reviews Drug Discovery, 2025).

Selected Publications


Zhou, M.-M., & Cole, P.A. (2025) Targeting Lysine Acetylation Readers and Writers. Nature Reviews Drug Discovery, 24(2):112-133.

Vann, K.R., Sharma, R., Hsu, C.-C., Devoucoux, M., Tencer, A.H., Zeng, L., Lin, K., Zhu, L., Li, Q., Lachance, C., Ospina, R.R., Tong, Q., Cheung, K.L., Yang, S., Xuan, H., Gatchalian, J., Alamillo, L., Wang, J., Jang, S.M., Klein, B.J., Lu, Y., Strahl, B.D., Rothbart, S.B., Walsh, M.J., Cleary, M.L., Côté, J., Shi, X., Zhou, M.-M.*, & Kutateladze, T.G.* (2025) Structure-Function Relationship of ASH1L and Histone H3K26 and H3K4 Methylation. Nature Commun., 16(1): 2235. PMID: 40044670.

Liu, N., Konuma, K., Sharma, R., Wang, D., Zhao, N., Cao, L.L., Ju, Y., Liu, D., Wang, Shui, Bosch, A., Sun, Y.F., Zhang, S., Ji, D.L., Nagatoishi, S., Suzuki, N., Kikuchi, M., Wakamori, M., Zhao, C.C., Ren, C.Y., Zhou, T.J.C., Xu. Y.Y., Meslamani, J., Fu, S.B., Umehara, T., Tsumoto, K., Akashi, S., Zeng, L., Roeder, R.G., Walsh, M.J., Zhang, Q., & Zhou, M.-M. (2023) Histone H3 Lysine 27 Crotonylation Mediates Gene Transcriptional Repression in Chromatin. Mol. Cell 83(13): 2206-2221.

Yu, D., Liang, Y., Kim, C., Jaganathan, A., Ji, D., Han, X., Yang, X., Jia, Y., Gu, R., Wang, C., Zhang, Q., Cheung, K.L., Zhou, M.-M., & Zeng, L. (2023) Structural Mechanism of BRD4-NUT and p300 Bipartite Interactions in Propagating Aberrant Gene Transcription in Chromatin in NUT Carcinoma. Nature Commun. 14(1): 378.

Han, X.Y., Yu, D., Gu, R.R., Jia, Y.J., Wang, Q., Yang, X.L., Yu, M.M., Babault, N., Zhao, C.C., Yi, H.F., Zhang, Q., Zhou, M.-M., & Zeng, L. (2020) Roles of BRD4 Short Isoform in Phase Separation for Active Gene Transcription. Nature Struct. & Mol. Biol., 27(4):333-341.

Shi, J., Wang, Y., Zeng, L., Wu, Y., Deng, J., Zhang, Q., Dong, C., Li, J., Rusinova, E., Zhang, G., Wang, C., Zhu, H., Evers, B.M., Zhou, M.-M.*, & Zhou, B.P.* (2014) Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer. Cancer Cell 25(2): 210-225.

Yap, K.L., Li, S., Munoz-Cabello, A.M., Raguz, S., Zeng, L., Mujtaba, S., Gil, J., Walsh, W.J., & Zhou, M.-M. (2010) Molecular Interplay of the Non-coding RNA ANRIL and Methylated Histone H3 Lysine 27 by Polycomb CBX7 in Transcriptional Silencing of INK4a. Mol. Cell 38(5): 662-674.

Zeng, L., Zhang, Q., Li, S.D., Plotnikov, A.N., Walsh, M.J., & Zhou, M.-M. (2010) Mechanism and Regulation of Acetylated Histone Binding of the Tandem PHD Finger of DPF3b. Nature 466(7303): 258-62.

Zeng, L., Li, J., Muller, M., Yan, S., Mujtaba, S., Pan, C., Wang, Z., & Zhou, M.-M. (2005) Selective Small Molecules Blocking HIV-1 Tat and Coactivator PCAF Association. Journal of Am. Chem. Soc. 127(8): 2376-2377.

Dhalluin, C., Carlson, J., Zeng, L., He, C., Aggarwal, A.K., & Zhou, M.-M. (1999) Structure and Ligand of a Histone Acetyltransferase Bromodomain. Nature 399(6735): 491-496.

PhD, Purdue University

Postdoctoral Fellow, Abbott Laboratories

2023

Prostate Cancer Foundation Challenge Award

2021

Fellow, the National Adademy of Inventors (NAI)

2019

The Jacobi Medallion, the Mount Sinai Health System

2012

Fellow, the American Association of the Advancement of Science (AAAS)

2003

GlaxoSmithKline Drug Discovery and Development Award

1999

American Cancer Society Young Investigator Award

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Zhou during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Board Service

  • Parkside Scientific Inc.
  • New York Structural Biology Center

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Parkside Scientific Inc.

Founder/Co-Founder/Partner

  • Parkside Scientific Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.